{"disease":{"id":"relapsed-refractory-indolent-b-cell-non-hodgkin-lymphoma","name":"relapsed refractory indolent b cell non hodgkin lymphoma"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT02384954","title":"QUILT-3.002: N-803 in Patients With Relapse/Refractory iNHL in Conjunction With Rituximab","phase":"PHASE1, PHASE2","overall_status":"TERMINATED","enrollment_count":43,"lead_sponsor_name":"Altor BioScience","has_results":true},{"nct_id":"NCT03985189","title":"Study of ME-401 in Subjects With Relapsed or Refractory Indolent B-cell Non-Hodgkin's Lymphoma","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":14,"lead_sponsor_name":"Kyowa Kirin Co., Ltd.","has_results":false}],"total":2},"guidelines":[],"source":"Drug Landscape verified database"}